Literature DB >> 28657311

Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.

Mohamed S A Elsayed1, Yafan Su1, Ping Wang1, Taresh Sethi2, Keli Agama2, Azhar Ravji2, Christophe E Redon2, Evgeny Kiselev2, Katharine A Horzmann3, Jennifer L Freeman3, Yves Pommier2, Mark Cushman1.   

Abstract

The 7-azaindenoisoquinolines are cytotoxic topoisomerase I (Top1) inhibitors. Previously reported representatives bear a 3-nitro group. The present report documents the replacement of the potentially genotoxic 3-nitro group by 3-chloro and 3-fluoro substituents, resulting in compounds with high Top1 inhibitory activities and potent cytotoxicities in human cancer cell cultures and reduced lethality in an animal model. Some of the new Top1 inhibitors also possess moderate inhibitory activities against tyrosyl-DNA phosphodiesterase 1 (TDP1) and tyrosyl-DNA phosphodiesterase 2 (TDP2), two enzymes that are involved in DNA damage repair resulting from Top1 inhibitors, and they produce significantly more DNA damage in cancer cells than in normal cells. Eighteen of the new compounds had cytotoxicity mean-graph midpoint (MGM) GI50 values in the submicromolar (0.033-0.630 μM) range. Compounds 16b and 17b are the most potent in human cancer cell cultures with MGM GI50 values of 0.063 and 0.033 μM, respectively. Possible binding modes to Top1 and TDP1were investigated by molecular modeling.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28657311      PMCID: PMC8025945          DOI: 10.1021/acs.jmedchem.6b01870

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  59 in total

1.  Derivation and validation of toxicophores for mutagenicity prediction.

Authors:  Jeroen Kazius; Ross McGuire; Roberta Bursi
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

Review 2.  End-processing nucleases and phosphodiesterases: An elite supporting cast for the non-homologous end joining pathway of DNA double-strand break repair.

Authors:  Vijay Menon; Lawrence F Povirk
Journal:  DNA Repair (Amst)       Date:  2016-05-18

3.  Tyrosyl-DNA Phosphodiesterase I a critical survival factor for neuronal development and homeostasis.

Authors:  Robert C A M van Waardenburg
Journal:  J Neurol Neuromedicine       Date:  2016

4.  Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.

Authors:  Muthukaman Nagarajan; Andrew Morrell; Alexandra Ioanoviciu; Smitha Antony; Glenda Kohlhagen; Keli Agama; Melinda Hollingshead; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

Review 5.  Zebrafish as a model vertebrate for investigating chemical toxicity.

Authors:  Adrian J Hill; Hiroki Teraoka; Warren Heideman; Richard E Peterson
Journal:  Toxicol Sci       Date:  2005-02-09       Impact factor: 4.849

6.  Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).

Authors:  Ping Wang; Mohamed S A Elsayed; Caroline B Plescia; Azhar Ravji; Christophe E Redon; Evgeny Kiselev; Christophe Marchand; Olga Zeleznik; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2017-04-18       Impact factor: 7.446

7.  Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.

Authors:  W D Kingsbury; J C Boehm; D R Jakas; K G Holden; S M Hecht; G Gallagher; M J Caranfa; F L McCabe; L F Faucette; R K Johnson
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

8.  TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.

Authors:  Hok Khim Fam; Cheryl Walton; Sheetal A Mitra; Miraj Chowdhury; Nichola Osborne; Kunho Choi; Guobin Sun; Patrick C W Wong; Maureen J O'Sullivan; Gulisa Turashvili; Samuel Aparicio; Timothy J Triche; Mason Bond; Catherine J Pallen; Cornelius F Boerkoel
Journal:  Mol Cancer Res       Date:  2013-08-02       Impact factor: 5.852

9.  Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.

Authors:  Smitha Antony; Muthusamy Jayaraman; Gary Laco; Glenda Kohlhagen; Kurt W Kohn; Mark Cushman; Yves Pommier
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

Review 10.  Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.

Authors:  Yang Xu; Chengtao Her
Journal:  Biomolecules       Date:  2015-07-22
View more
  9 in total

1.  The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.

Authors:  Laetitia Marzi; Yilun Sun; Shar-Yin N Huang; Amy James; Simone Difilippantonio; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2020-05-19       Impact factor: 6.261

2.  The influence of an enamine usnic acid derivative (a tyrosyl-DNA phosphodiesterase 1 inhibitor) on the therapeutic effect of topotecan against transplanted tumors in vivo.

Authors:  V P Nikolin; N A Popova; V I Kaledin; O A Luzina; A L Zakharenko; N F Salakhutdinov; O I Lavrik
Journal:  Clin Exp Metastasis       Date:  2021-08-09       Impact factor: 5.150

3.  Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.

Authors:  Xiao-Ru Zhang; Hao-Wen Wang; Wen-Lin Tang; Yu Zhang; Hui Yang; De-Xuan Hu; Azhar Ravji; Christophe Marchand; Evgeny Kiselev; Kwabena Ofori-Atta; Keli Agama; Yves Pommier; Lin-Kun An
Journal:  J Med Chem       Date:  2018-10-31       Impact factor: 7.446

4.  Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Authors:  Laetitia Marzi; Keli Agama; Junko Murai; Simone Difilippantonio; Amy James; Cody J Peer; William D Figg; Daniel Beck; Mohamed S A Elsayed; Mark Cushman; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2018-05-10       Impact factor: 6.261

5.  Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity.

Authors:  Mostafa M Elbadawi; Wagdy M Eldehna; Wenjie Wang; Keli K Agama; Yves Pommier; Manabu Abe
Journal:  Eur J Med Chem       Date:  2021-02-09       Impact factor: 7.088

Review 6.  Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.

Authors:  Mary-Ann Bjornsti; Scott H Kaufmann
Journal:  F1000Res       Date:  2019-09-30

Review 7.  Diphenyl Ditelluride: Redox-Modulating and Antiproliferative Properties.

Authors:  Cristiano Trindade; André Luiz Mendes Juchem; Temenouga N Guecheva; Iuri M de Oliveira; Priscila Dos Santos Silveira; José Eduardo Vargas; Renato Puga; Claudia Ó Pessoa; João A P Henriques
Journal:  Oxid Med Cell Longev       Date:  2019-10-24       Impact factor: 6.543

8.  2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.

Authors:  Mostafa M Elbadawi; Wagdy M Eldehna; Amer Ali Abd El-Hafeez; Warda R Somaa; Amgad Albohy; Sara T Al-Rashood; Keli K Agama; Eslam B Elkaeed; Pradipta Ghosh; Yves Pommier; Manabu Abe
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

9.  Design, Synthesis, and Antiproliferative Evaluation of Novel Coumarin/2-Cyanoacryloyl Hybrids as Apoptosis Inducing Agents by Activation of Caspase-Dependent Pathway.

Authors:  Yu-Ying Zhang; Qian-Qian Zhang; Jia-Li Song; Liang Zhang; Cheng-Shi Jiang; Hua Zhang
Journal:  Molecules       Date:  2018-08-07       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.